Urticaria: A review

Tasneem Poonawalla, Brent Kelly

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

Urticaria is often classified as acute, chronic, or physical based on duration of symptoms and the presence or absence of inducing stimuli. Urticarial vasculitis, contact urticaria, and special syndromes are also included under the broad heading of urticaria. Recent advances in our understanding of the pathogenesis of chronic urticaria include the finding of autoantibodies to mast cell receptors in nearly half of patients with chronic idiopathic urticaria. These patients may have more severe disease and require more aggressive therapies. Extensive laboratory evaluation for patients with chronic urticaria is typically unrevealing and there are no compelling data that associate urticaria with chronic infections or malignancy. Pharmacologic therapy consists primarily of the appropriate use of first- and second-generation histamine H1 receptor antihistamines. Additional therapy may include leukotriene receptor antagonists, corticosteroids, and immunomodulatory agents for severe, unremitting disease. Despite our greater understanding of the pathogenesis of urticaria, the condition remains a frustrating entity for many patients, particularly those with chronic urticaria.

Original languageEnglish (US)
Pages (from-to)9-21
Number of pages13
JournalAmerican Journal of Clinical Dermatology
Volume10
Issue number1
DOIs
StatePublished - 2009

Fingerprint

Urticaria
Leukotriene Antagonists
Histamine H1 Receptors
Histamine Antagonists
Vasculitis
Mast Cells
Autoantibodies
Adrenal Cortex Hormones
Therapeutics
Infection

Keywords

  • Antidepressants, therapeutic use
  • Corticosteroids, therapeutic use
  • Histamine H1 receptor antagonists, therapeutic use
  • Histamine H2 receptor antagonists, therapeutic use
  • Immune globulin, therapeutic use
  • Leukotriene receptor antagonists, therapeutic use

ASJC Scopus subject areas

  • Dermatology

Cite this

Urticaria : A review. / Poonawalla, Tasneem; Kelly, Brent.

In: American Journal of Clinical Dermatology, Vol. 10, No. 1, 2009, p. 9-21.

Research output: Contribution to journalArticle

Poonawalla, Tasneem ; Kelly, Brent. / Urticaria : A review. In: American Journal of Clinical Dermatology. 2009 ; Vol. 10, No. 1. pp. 9-21.
@article{c4f67b22daa44f4581c676e067b23a77,
title = "Urticaria: A review",
abstract = "Urticaria is often classified as acute, chronic, or physical based on duration of symptoms and the presence or absence of inducing stimuli. Urticarial vasculitis, contact urticaria, and special syndromes are also included under the broad heading of urticaria. Recent advances in our understanding of the pathogenesis of chronic urticaria include the finding of autoantibodies to mast cell receptors in nearly half of patients with chronic idiopathic urticaria. These patients may have more severe disease and require more aggressive therapies. Extensive laboratory evaluation for patients with chronic urticaria is typically unrevealing and there are no compelling data that associate urticaria with chronic infections or malignancy. Pharmacologic therapy consists primarily of the appropriate use of first- and second-generation histamine H1 receptor antihistamines. Additional therapy may include leukotriene receptor antagonists, corticosteroids, and immunomodulatory agents for severe, unremitting disease. Despite our greater understanding of the pathogenesis of urticaria, the condition remains a frustrating entity for many patients, particularly those with chronic urticaria.",
keywords = "Antidepressants, therapeutic use, Corticosteroids, therapeutic use, Histamine H1 receptor antagonists, therapeutic use, Histamine H2 receptor antagonists, therapeutic use, Immune globulin, therapeutic use, Leukotriene receptor antagonists, therapeutic use",
author = "Tasneem Poonawalla and Brent Kelly",
year = "2009",
doi = "10.2165/0128071-200910010-00002",
language = "English (US)",
volume = "10",
pages = "9--21",
journal = "American Journal of Clinical Dermatology",
issn = "1175-0561",
publisher = "Adis International Ltd",
number = "1",

}

TY - JOUR

T1 - Urticaria

T2 - A review

AU - Poonawalla, Tasneem

AU - Kelly, Brent

PY - 2009

Y1 - 2009

N2 - Urticaria is often classified as acute, chronic, or physical based on duration of symptoms and the presence or absence of inducing stimuli. Urticarial vasculitis, contact urticaria, and special syndromes are also included under the broad heading of urticaria. Recent advances in our understanding of the pathogenesis of chronic urticaria include the finding of autoantibodies to mast cell receptors in nearly half of patients with chronic idiopathic urticaria. These patients may have more severe disease and require more aggressive therapies. Extensive laboratory evaluation for patients with chronic urticaria is typically unrevealing and there are no compelling data that associate urticaria with chronic infections or malignancy. Pharmacologic therapy consists primarily of the appropriate use of first- and second-generation histamine H1 receptor antihistamines. Additional therapy may include leukotriene receptor antagonists, corticosteroids, and immunomodulatory agents for severe, unremitting disease. Despite our greater understanding of the pathogenesis of urticaria, the condition remains a frustrating entity for many patients, particularly those with chronic urticaria.

AB - Urticaria is often classified as acute, chronic, or physical based on duration of symptoms and the presence or absence of inducing stimuli. Urticarial vasculitis, contact urticaria, and special syndromes are also included under the broad heading of urticaria. Recent advances in our understanding of the pathogenesis of chronic urticaria include the finding of autoantibodies to mast cell receptors in nearly half of patients with chronic idiopathic urticaria. These patients may have more severe disease and require more aggressive therapies. Extensive laboratory evaluation for patients with chronic urticaria is typically unrevealing and there are no compelling data that associate urticaria with chronic infections or malignancy. Pharmacologic therapy consists primarily of the appropriate use of first- and second-generation histamine H1 receptor antihistamines. Additional therapy may include leukotriene receptor antagonists, corticosteroids, and immunomodulatory agents for severe, unremitting disease. Despite our greater understanding of the pathogenesis of urticaria, the condition remains a frustrating entity for many patients, particularly those with chronic urticaria.

KW - Antidepressants, therapeutic use

KW - Corticosteroids, therapeutic use

KW - Histamine H1 receptor antagonists, therapeutic use

KW - Histamine H2 receptor antagonists, therapeutic use

KW - Immune globulin, therapeutic use

KW - Leukotriene receptor antagonists, therapeutic use

UR - http://www.scopus.com/inward/record.url?scp=58849122700&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58849122700&partnerID=8YFLogxK

U2 - 10.2165/0128071-200910010-00002

DO - 10.2165/0128071-200910010-00002

M3 - Article

C2 - 19170406

AN - SCOPUS:58849122700

VL - 10

SP - 9

EP - 21

JO - American Journal of Clinical Dermatology

JF - American Journal of Clinical Dermatology

SN - 1175-0561

IS - 1

ER -